Your browser doesn't support javascript.
loading
Prevention of chronic renal allograft rejection by AS2553627, a novel JAK inhibitor, in a rat transplantation model.
Nakamura, Koji; Kawato, Yuka; Kaneko, Yoko; Hanaoka, Kaori; Kubo, Kaori; Nakanishi, Tomonori; Maeda, Masashi; Fukahori, Hidehiko; Ito, Misato; Noto, Takahisa; Inami, Masamichi; Hirose, Jun; Morokata, Tatsuaki.
Afiliação
  • Nakamura K; Drug Discovery Research,Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan. Electronic address: koji.nakamura@astellas.com.
  • Kawato Y; Drug Discovery Research,Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.
  • Kaneko Y; Drug Discovery Research,Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.
  • Hanaoka K; Drug Discovery Research,Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.
  • Kubo K; Drug Discovery Research,Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.
  • Nakanishi T; Drug Discovery Research,Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.
  • Maeda M; Drug Discovery Research,Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.
  • Fukahori H; Drug Discovery Research,Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.
  • Ito M; Drug Discovery Research,Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.
  • Noto T; Drug Discovery Research,Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.
  • Inami M; Drug Discovery Research,Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.
  • Hirose J; Drug Discovery Research,Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.
  • Morokata T; Drug Discovery Research,Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.
Transpl Immunol ; 46: 14-20, 2018 02.
Article em En | MEDLINE | ID: mdl-28988984
BACKGROUND: Janus kinase (JAK) inhibitors are thought to be promising candidates to aid renal transplantation. However, the effectiveness of JAK inhibitors against features of chronic rejection, including interstitial fibrosis/tubular atrophy (IF/TA) and glomerulosclerosis, has not been elucidated. Here, we investigated the effect of AS2553627, a novel JAK inhibitor, on the development of chronic rejection in rat renal transplantation. METHODS: Lewis (LEW) to Brown Norway (BN) rat renal transplantation was performed. Tacrolimus (TAC) at 0.1mg/kg was administered intramuscularly once a day for 10 consecutive days starting on the day of transplantation (days 0 to 9) to prevent initial acute rejection. After discontinuation of TAC treatment from days 10 to 28, AS2553627 (1 and 10mg/kg) was orally administered with TAC. At 13weeks after renal transplantation, grafts were harvested for histopathological and mRNA analysis. Creatinine and donor-specific antibodies were measured from plasma samples. Urinary protein and kidney injury markers were also evaluated. RESULTS: AS2553627 in combination with TAC exhibited low plasma creatinine and a marked decrease in urinary protein and kidney injury markers, such as tissue inhibitor of metalloproteinase-1 and kidney injury molecule-1. At 13weeks, histopathological analysis revealed that AS2553627 treatment inhibited glomerulosclerosis and IF/TA. In addition, upregulation of cell surface markers, fibrosis/epithelial-mesenchymal transition and inflammation-related genes were reduced by the combination of AS2553672 and TAC, particularly CD8 and IL-6 mRNAs, indicating that AS2553627 prevented cell infiltration and inflammation in renal allografts. CONCLUSIONS: These results indicate the therapeutic potential of JAK inhibitors in chronic rejection progression, and suggest that AS2553627 is a promising agent to improve long-term graft survival after renal transplantation.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperidinas / Pirróis / Glomerulosclerose Segmentar e Focal / Transplante de Rim / Aloenxertos / Rejeição de Enxerto Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Transpl Immunol Assunto da revista: ALERGIA E IMUNOLOGIA / TRANSPLANTE Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperidinas / Pirróis / Glomerulosclerose Segmentar e Focal / Transplante de Rim / Aloenxertos / Rejeição de Enxerto Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Transpl Immunol Assunto da revista: ALERGIA E IMUNOLOGIA / TRANSPLANTE Ano de publicação: 2018 Tipo de documento: Article